Profile data is unavailable for this security.
About the company
Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
- Revenue in USD (TTM)0.00
- Net income in USD-19.29m
- Incorporated2006
- Employees13.00
- LocationAptose Biosciences Inc66 Wellington Street WestSuite 5300,, TD Bank Tower Box 48TORONTO MK5 1E6CanadaCAN
- Phone+1 (647) 479-9828
- Fax+1 (416) 798-2200
- Websitehttps://aptose.com/
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 30 Sep 2025 | 19.76k | 0.77% |
| The Gleason Group, Inc.as of 31 Dec 2025 | 4.21k | 0.17% |
| Farther Finance Advisors LLCas of 31 Dec 2025 | 10.00 | 0.00% |
| Caldwell Sutter Capital, Inc. (Investment Management)as of 31 Dec 2025 | 2.00 | 0.00% |
